Ocular device delivery methods and systems

Abstract

The present disclosure provides an ophthalmic article. The ophthalmic article may comprise a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer. The ophthalmic article may also comprise an active agent or a diagnostic agent. The ophthalmic article may be configured to associate to a haptic of an intraocular lens (IOL).

What is claimed is: 
     
         1 .- 71 . (canceled) 
     
     
         72 . An ophthalmic article, comprising:
 a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer; and   an active agent or a diagnostic agent;   wherein the ophthalmic article has an elasticity modulus of at most 10 MPa, as measured by dynamic mechanical analysis, and wherein the ophthalmic article is structurally configured to recover its original shape after injection through an injector that comprises an injector tip inner diameter from about 0.5 mm to about 3 mm.   
     
     
         73 . The ophthalmic article of  claim 72 , wherein the ophthalmic article is configured to associate with an ocular device. 
     
     
         74 . The ophthalmic article of  claim 73 , wherein the ophthalmic article is configured to associate compressively with the ocular device. 
     
     
         75 . The ophthalmic article of  claim 73 , wherein the ocular device is an intraocular lens (IOL). 
     
     
         76 . The ophthalmic article of  claim 75 , wherein the ophthalmic article is configured to exclusively associate with a haptic of the IOL. 
     
     
         77 . The ophthalmic article of  claim 76 , wherein the ophthalmic article extends no more than 0.32 mm beyond the haptic of the IOL once the ophthalmic article is associated to the haptic of the IOL. 
     
     
         78 . The ophthalmic article of  claim 73 , wherein the ophthalmic article is structurally configured to encircle at least 51% of the circumference of an appendage of the ocular device. 
     
     
         79 . The ophthalmic article of  claim 78 , wherein the appendage comprises a notched region, and wherein the ophthalmic article is configured to associate with the notched region of the appendage. 
     
     
         80 . The ophthalmic article of  claim 73 , wherein the ophthalmic article comprises an internal structure configured to associate with the ocular device. 
     
     
         81 . The ophthalmic article of  claim 72 , wherein the ophthalmic article is structurally configured to associate with the ocular device without the use of an external force or external agent. 
     
     
         82 . The ophthalmic article of  claim 72 , wherein the ophthalmic article comprises from about 50 to 300 μg of the active agent or the diagnostic agent. 
     
     
         83 . The ophthalmic article of  claim 72 , wherein the ophthalmic article provides a sustained release of the active agent or the diagnostic agent over a period of from about 1 week to about 12 weeks. 
     
     
         84 . The ophthalmic article of  claim 72 , wherein the ophthalmic article has an elongation at break of at least about 100% as measured at from about 18° C. to 24° C. 
     
     
         85 . The ophthalmic article of  claim 72 , wherein the at least one other monomer is lactide, glycolide, or trimethylene carbonate. 
     
     
         86 . The ophthalmic article of  claim 72 , wherein the active agent is a corticosteroid, non-steroidal anti-inflammatory drug, or antibiotic. 
     
     
         87 . The ophthalmic article of  claim 72 , wherein the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. 
     
     
         88 . The ophthalmic article of  claim 72 , wherein the active agent or the diagnostic agent is at most about 35% by weight of the ophthalmic article. 
     
     
         89 . An ophthalmic article, comprising:
 a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer; and   an active agent or a diagnostic agent;   wherein the ophthalmic article has an elasticity modulus of at most 10 MPa, as measured by dynamic mechanical analysis, and wherein the ophthalmic article is structurally configured to compressively associate with an ocular device without the use of an external force or external agent.   
     
     
         90 . An ophthalmic article, comprising:
 a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer; and   an active agent or a diagnostic agent;   wherein the ophthalmic article comprises an internal structure for associating around an outer surface of a haptic of an intraocular lens (IOL), and wherein a perimeter of the internal structure is less than or equal to about 2.2 mm.   
     
     
         91 . A method of treating or preventing a disease, comprising:
 implanting into an eye of a subject in need thereof an ocular device for sustained intraocular drug delivery, wherein the ocular device comprises one or more drug release articles associated thereto, wherein the one or more drug release articles comprises:   a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer; and   an active agent or a diagnostic agent, wherein the one or more drug release articles has an elasticity modulus of at most 10 MPa, as measured by dynamic mechanical analysis, and wherein the one or more drug release articles is structurally configured to recover its original shape after injection through an injector that comprises an injector tip inner diameter from about 0.5 mm to about 3 mm.